Brahami Menaouer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brahami Menaouer has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Nada Matta
University of Technology of Troyes, France
10 shared publicationsMatta Nada
TechCICO Laboratory, University of Technology of Troyes, Troyes, France
5 shared publicationsSabri Mohammed
4 shared publications- Sabri Mohammed
National Polytechnic School of Oran, Algeria
4 shared publications - Fatma Zahra Abdeldjouad
LABAB Laboratory, Computer Systems Engineering Department, National Polytechnic School of Oran – Maurice Audin, Oran, Algeria
3 shared publications Khalissa Semaoune
LREEM Laboratory, University of Oran 2, Algeria
3 shared publications
Latest Publications
- 13 April 2026
- Published by Springer Nature in Iran Journal of Computer Science
- Vol. 9 (1)
Pharmaceutical chatbot assistant using generative AI and knowledge graph with specific pharmaceutical resources
- 13 April 2026
- Published by Springer Nature in Iran Journal of Computer Science
- Vol. 9 (1)
Pharmaceutical chatbot assistant using generative AI and knowledge graph with specific pharmaceutical resources
- 13 April 2026
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 15 (1) , 113
Automated detection of adverse drug reactions from twitter and PsyTAR using supervised machine learning models
- 13 April 2026
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 15 (1) , 113
Automated detection of adverse drug reactions from twitter and PsyTAR using supervised machine learning models
- Open Access
- 16 October 2025
- Published by Springer Nature in Research Square
Pharmaceutical ChatBot Assistant Using Generative AI and Knowledge Graph with Specific Pharmaceutical Resources
Artificial Intelligence (AI) has the potential to revolutionize the medical and pharmaceutical sectors. AI and related technologies can significantly address some supply and demand challenges in the pharmaceutical system, such as pharmaceutical AI assistants, chatbot technology, and PharmaRobots. Generative AI (GenAI) is a type of AI that aims to produce new content rather than merely recognizing it. One of the most significant advances in Natural Language Processing (NLP) in recent years is the development of Large Language Models (LLMs). In this study, we propose a chatbot system to support pharmacists through the development of a pharmaceutical chatbot assistant, called PharmaBot, which is proficient in delivering accurate and contextually relevant responses concerning medications. To this end, we developed a general architectural design that focuses on tailoring LLMs, utilizing Retrieval-Augmented Generation (RAG) and Knowledge Graphs (KGs) to evaluate their performance with specific pharmaceutical resources. A comprehensive knowledge base was constructed by meticulously preprocessing 18,698 pharmaceutical files from the Vidal Group. A key innovation is a dual-embedding strategy that captures both semantic and structural information to facilitate nuanced and context-aware similarity searches. By adopting sophisticated evaluation measures such as ROUGE, BERTScore, METEOR, and Cosine Similarity, the effectiveness of the algorithms used in producing precise and cohesive summaries was evaluated. Based on the aggregated proposals and findings in the existing literature, this paper concludes with a set of challenges and research recommendations, hopefully contributing to guiding research in the extremely active pharmaceutical domain.
- 16 October 2025
- Published by Springer Nature in Research Square
Open AccessPharmaceutical ChatBot Assistant Using Generative AI and Knowledge Graph with Specific Pharmaceutical Resources
Artificial Intelligence (AI) has the potential to revolutionize the medical and pharmaceutical sectors. AI and related technologies can significantly address some supply and demand challenges in the pharmaceutical system, such as pharmaceutical AI assistants, chatbot technology, and PharmaRobots. Generative AI (GenAI) is a type of AI that aims to produce new content rather than merely recognizing it. One of the most significant advances in Natural Language Processing (NLP) in recent years is the development of Large Language Models (LLMs). In this study, we propose a chatbot system to support pharmacists through the development of a pharmaceutical chatbot assistant, called PharmaBot, which is proficient in delivering accurate and contextually relevant responses concerning medications. To this end, we developed a general architectural design that focuses on tailoring LLMs, utilizing Retrieval-Augmented Generation (RAG) and Knowledge Graphs (KGs) to evaluate their performance with specific pharmaceutical resources. A comprehensive knowledge base was constructed by meticulously preprocessing 18,698 pharmaceutical files from the Vidal Group. A key innovation is a dual-embedding strategy that captures both semantic and structural information to facilitate nuanced and context-aware similarity searches. By adopting sophisticated evaluation measures such as ROUGE, BERTScore, METEOR, and Cosine Similarity, the effectiveness of the algorithms used in producing precise and cohesive summaries was evaluated. Based on the aggregated proposals and findings in the existing literature, this paper concludes with a set of challenges and research recommendations, hopefully contributing to guiding research in the extremely active pharmaceutical domain.
- 1 June 2024
- Published by Springer Nature in International Journal of Information Technology
- Vol. 17 (9) , 5455-5466
Supervised learning techniques for blood product prediction in patients with hematologic diseases: a multi-centre study in Western Algeria
- 1 June 2024
- Published by Springer Nature in International Journal of Information Technology
- Vol. 17 (9) , 5455-5466
Supervised learning techniques for blood product prediction in patients with hematologic diseases: a multi-centre study in Western Algeria
- Open Access
Evaluating the Effectiveness of Artificial Intelligence in Predicting Adverse Drug Reactions among Cancer Patients: A Systematic Review and Meta-Analysis
Adverse drug reactions considerably impact patient outcomes and healthcare costs in cancer therapy. Using artificial intelligence to predict adverse drug reactions in real time could revolutionize oncology treatment. This study aims to assess the performance of artificial intelligence models in predicting adverse drug reactions in patients with cancer. This is the first systematic review and meta-analysis. Scopus, PubMed, IEEE Xplore, and ACM Digital Library databases were searched for studies in English, French, and Arabic from January 1, 2018, to August 20, 2023. The inclusion criteria were: (1) peer-reviewed research articles; (2) use of artificial intelligence algorithms (machine learning, deep learning, knowledge graphs); (3) study aimed to predict adverse drug reactions (cardiotoxicity, neutropenia, nephrotoxicity, hepatotoxicity); (4) study was on cancer patients. The data were extracted and evaluated by three reviewers for study quality. Of the 332 screened articles, 17 studies (5%) involving 93,248 oncology patients from 17 countries were included in the systematic review, of which ten studies synthesized the meta-analysis. A random-effects model was created to pool the sensitivity, specificity, and AUC of the included studies. The pooled results were 0.82 (95% CI:0.69, 0.9), 0.84 (95% CI:0.75, 0.9), and 0.83 (95% CI:0.77, 0.87) for sensitivity, specificity, and AUC, respectively, of ADR predictive models. Biomarkers proved their effectiveness in predicting ADRs, yet they were adopted by only half of the reviewed studies. The use of AI in cancer treatment shows great potential, with models demonstrating high specificity and sensitivity in predicting ADRs. However, standardized research and multicenter studies are needed to improve the quality of evidence. AI can enhance cancer patient care by bridging the gap between data-driven insights and clinical expertise.
Open AccessEvaluating the Effectiveness of Artificial Intelligence in Predicting Adverse Drug Reactions among Cancer Patients: A Systematic Review and Meta-Analysis
Adverse drug reactions considerably impact patient outcomes and healthcare costs in cancer therapy. Using artificial intelligence to predict adverse drug reactions in real time could revolutionize oncology treatment. This study aims to assess the performance of artificial intelligence models in predicting adverse drug reactions in patients with cancer. This is the first systematic review and meta-analysis. Scopus, PubMed, IEEE Xplore, and ACM Digital Library databases were searched for studies in English, French, and Arabic from January 1, 2018, to August 20, 2023. The inclusion criteria were: (1) peer-reviewed research articles; (2) use of artificial intelligence algorithms (machine learning, deep learning, knowledge graphs); (3) study aimed to predict adverse drug reactions (cardiotoxicity, neutropenia, nephrotoxicity, hepatotoxicity); (4) study was on cancer patients. The data were extracted and evaluated by three reviewers for study quality. Of the 332 screened articles, 17 studies (5%) involving 93,248 oncology patients from 17 countries were included in the systematic review, of which ten studies synthesized the meta-analysis. A random-effects model was created to pool the sensitivity, specificity, and AUC of the included studies. The pooled results were 0.82 (95% CI:0.69, 0.9), 0.84 (95% CI:0.75, 0.9), and 0.83 (95% CI:0.77, 0.87) for sensitivity, specificity, and AUC, respectively, of ADR predictive models. Biomarkers proved their effectiveness in predicting ADRs, yet they were adopted by only half of the reviewed studies. The use of AI in cancer treatment shows great potential, with models demonstrating high specificity and sensitivity in predicting ADRs. However, standardized research and multicenter studies are needed to improve the quality of evidence. AI can enhance cancer patient care by bridging the gap between data-driven insights and clinical expertise.
- 1 January 2024
- Published by Springer Nature
- p. 350-362
Blood Product Prediction Using Supervised Machine Learning
- 1 January 2024
- Published by Springer Nature
- p. 350-362
Blood Product Prediction Using Supervised Machine Learning
- Open Access
- 1 January 2023
- Published by IGI Global Scientific Publishing in International Journal of Intelligent Information Technologies
- Vol. 19 (1) , 1-22
Android Malware Detection Approach Using Stacked AutoEncoder and Convolutional Neural Networks
In the past decade, Android has become a standard smartphone operating system. The mobile devices running on the Android operating system are particularly interesting to malware developers, as the users often keep personal information on their mobile devices. This paper proposes a deep learning model for mobile malware detection and classification. It is based on SAE for reducing the data dimensionality. Then, a CNN is utilized to detect and classify malware apps in Android devices through binary visualization. Tests were carried out with an original Android application (Drebin-215) dataset consisting of 15,036 applications. The conducted experiments prove that the classification performance achieves high accuracy of about 98.50%. Other performance measures used in the study are precision, recall, and F1-score. Finally, the accuracy and results of these techniques are analyzed by comparing the effectiveness with previous works.
- 1 January 2023
- Published by IGI Global Scientific Publishing in International Journal of Intelligent Information Technologies
- Vol. 19 (1) , 1-22
Open AccessAndroid Malware Detection Approach Using Stacked AutoEncoder and Convolutional Neural Networks
In the past decade, Android has become a standard smartphone operating system. The mobile devices running on the Android operating system are particularly interesting to malware developers, as the users often keep personal information on their mobile devices. This paper proposes a deep learning model for mobile malware detection and classification. It is based on SAE for reducing the data dimensionality. Then, a CNN is utilized to detect and classify malware apps in Android devices through binary visualization. Tests were carried out with an original Android application (Drebin-215) dataset consisting of 15,036 applications. The conducted experiments prove that the classification performance achieves high accuracy of about 98.50%. Other performance measures used in the study are precision, recall, and F1-score. Finally, the accuracy and results of these techniques are analyzed by comparing the effectiveness with previous works.